Active substances
Hydrochlorothiazide + Spironolactone
- US FDA 20
- Health Canada 2
- US price lines 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ALDACTAZIDE | 25MG;25MG | tablet · oral | PFIZER | Prescription | 27 Jan 1961 |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | MYLAN | Prescription | 3 Aug 1979 |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | SUN PHARM INDUSTRIES | Prescription | 2 Jul 1987 |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | RUBICON RESEARCH | Prescription | 10 Sep 2026 |
| ALDACTAZIDE | 50MG;50MG | tablet · oral | PFIZER | Discontinued | 27 Jan 1961 |
| SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | IVAX PHARMS | Discontinued | 7 May 1980 |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | CHARTWELL RX | Discontinued | 10 Jul 1980 |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | MUTUAL PHARM | Discontinued | 16 Apr 1981 |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | WATSON LABS | Discontinued | 24 Nov 1981 |
| SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | VANGARD | Discontinued | 14 Dec 1981 |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | SUPERPHARM | Discontinued | 26 Aug 1985 |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | PUREPAC PHARM | Discontinued | 6 Nov 1985 |
| SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | WATSON LABS | Discontinued | |
| SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | WATSON LABS | Discontinued | |
| SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | LEDERLE | Discontinued | |
| SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | UPSHER SMITH | Discontinued | |
| SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | USL PHARMA | Discontinued | |
| SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | PARKE DAVIS | Discontinued | |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | ASCOT | Discontinued | |
| SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE | 25MG;25MG | tablet · oral | PUREPAC PHARM | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| TEVA-SPIRONOLACTONE/HCTZ | 00613231 | 25 MG; 25 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-SPIRONOLACTONE/HCTZ | 00657182 | 50 MG; 50 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SPIRONOLACTONE-HYDROCHLOROTHIAZIDE 25-25 TAB | $0.48325 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.